Based on the results of this Phase 3 study, the Company plans to
file marketing applications for abiraterone acetate with regulatory
authorities worldwide

Note: Data in this release correspond to ESMO abstract LBA5

RARITAN, N.J.,
Oct. 11 /PRNewswire/ -- Results from
a pre-specified interim analysis of a randomized,
placebo-controlled Phase 3 study, COU-AA-301, demonstrate that
patients treated with the investigational agent abiraterone acetate
plus low-dose prednisone/prednisolone showed a significant
improvement in overall survival compared to patients treated with
prednisone/prednisolone plus placebo. This study included 1,195
patients with metastatic advanced prostate cancer (also referred to
as castration-resistant prostate cancer, or CRPC) previously
treated with one or two chemotherapy regimens, at least one of
which contained docetaxel.

The results of this randomized, placebo-controlled
study were shared during a late-breaking presentation at the
Presidential Symposium today at the 35th Annual European Society
for Medical Oncology (ESMO) Congress.

"Abiraterone acetate has the potential to meet a
significant unmet need, so this news will be incredibly important
to prostate cancer patients and their families," said Johann S. de Bono, MD, FRCP, MSc, PhD, The
Institute of Cancer Research, The Royal Marsden NHS Foundation
Trust, one of the lead COU-AA-301 investigators. "We are very
pleased with the definitive results of this rigorous study, which
show that abiraterone acetate may extend survival for men with
metastatic advanced prostate cancer that progressed after treatment
with docetaxel."

The Company plans to file marketing applications for
abiraterone acetate with regulatory authorities in the U.S. and
Europe by the end of the year.
Applications in the rest of the world will follow, according
to local regulatory requirements. If approved, abiraterone
acetate will be commercialized and distributed by Centocor Ortho
Biotech Inc. in the U.S. and by Janssen Pharmaceutical Companies in
all other countries around the world.

"Globally, prostate cancer, the fifth most common
cancer overall, is a significant public health problem," said
Howard I. Scher, MD, Memorial
Sloan-Kettering Cancer Center, one of the lead COU-AA-301
investigators. "These results are important because men with
progressive metastatic, castration-resistant prostate cancer often
have a poor prognosis and currently have few treatment options."

A program that provides early access to abiraterone
acetate for eligible patients is expected to be opened in the U.S.
in October and will be opened in sites outside the U.S. in the
following months, with the timing of the program contingent on
local health authority and ethics committee approvals.

"The results of this abiraterone acetate Phase 3 study
in patients with metastatic advanced prostate cancer bring us
closer to achieving our goal of developing extraordinary
preventive, diagnostic and therapeutic solutions based on our tumor
microenvironment strategy," said William N.
Hait, MD, PhD, Global Therapeutic Head, Oncology, Ortho
Biotech Oncology Research & Development. "We believe that
abiraterone acetate is an important medical advance, and we look
forward to further developing oncology therapeutic options that may
impact patients' lives."

Ortho Biotech Oncology Research & Development, a
unit of Cougar Biotechnology, Inc., previously announced that the
Independent Data Monitoring Committee recommended unblinding this
Phase 3 study after a pre-specified interim analysis demonstrated a
statistically significant improvement in median overall survival
and an acceptable safety profile. The IDMC also recommended
that patients in the prednisone/prednisolone plus placebo group be
offered treatment with abiraterone acetate.

Abiraterone acetate is a novel, targeted,
investigational, oral androgen biosynthesis inhibitor being
developed for the treatment of metastatic advanced prostate cancer
that has progressed after developing resistance to conventional
hormonal therapies. This is also known as
castration-resistant prostate cancer (CRPC).

About Prostate Cancer

Prostate cancer occurs when cancer cells form in the
tissues of the prostate. The prostate is a gland located
around the urethra (under the bladder) in men that produces part of
the seminal fluid. In some cases, cancer of the prostate can
grow slowly compared with other cancers. However, depending
on factors including characteristics specific to the patient and
the tumor, prostate cancer can also grow very quickly and spread to
other places such as the lymph nodes, bones or other parts of the
body. Prostate cancer is considered to be advanced once it has
spread beyond the prostate region.

Globally, prostate cancer is the second most frequently
diagnosed cancer in men and the fifth most common cancer overall.
More than 900,000 new cases of prostate cancer were diagnosed
in 2008 and more than 258,000 men died from the disease, a 16
percent increase from 2002. In the U.S., an estimated 217,000
new cases of prostate cancer and 32,000 related deaths are expected
to be reported in 2010. Prostate cancer represents almost
one-third of all new cancer diagnoses in men (excluding basal cell
carcinoma) and is the second-leading cause of cancer-related death
in men.

Ortho Biotech Oncology Research & Development, a
unit of Cougar Biotechnology, Inc. partners with affiliated units
and companies in the Janssen Pharmaceutical Companies of Johnson
& Johnson such as Centocor Ortho Biotech Inc. and Janssen in
the research and development of oncology and supportive care
treatments.

Centocor Ortho Biotech Inc. redefines the standard of
care in immunology, nephrology and oncology. The company was
formed when Centocor, Inc. and Ortho Biotech Inc. were consolidated
in late 2008, and was renamed Centocor Ortho Biotech Inc.
Built upon a pioneering history, Centocor Ortho Biotech Inc.
harnesses innovations in large-molecule and small-molecule research
to create important new therapeutic options. Beyond its
innovative medicines, Centocor Ortho Biotech is at the forefront of
developing education and public policy initiatives to ensure
patients and their families, caregivers, advocates and healthcare
professionals have access to the latest treatment information,
support services and quality care. For more information about
Centocor Ortho Biotech, visit www.centocororthobiotech.com.

(This press release contains "forward-looking
statements" as defined in the Private Securities Litigation Reform
Act of 1995. These statements are based on current expectations of
future events. If underlying assumptions prove inaccurate or
unknown risks or uncertainties materialize, actual results could
vary materially from J&JPRD and/or Johnson & Johnson's
expectations and projections. Risks and uncertainties include
general industry conditions and competition; economic conditions,
such as interest rate and currency exchange rate fluctuations;
technological advances and patents attained by competitors;
challenges inherent in new product development, including obtaining
regulatory approvals; domestic and foreign health care reforms and
governmental laws and regulations; and trends toward health care
cost containment. A further list and description of these risks,
uncertainties and other factors can be found in Exhibit 99 of
Johnson & Johnson's Annual Report on Form 10-K for the fiscal
year ended January 3, 2010. Copies of
this Form 10-K, as well as subsequent filings, are available online
atwww.sec.gov,www.jnj.comor on
request from Johnson & Johnson. Neither J&JPRD nor Johnson
& Johnson undertake to update any forward-looking statements as
a result of new information or future events or
developments.)